Table 4.
Comparison of frequently identified mutated oncogenic genes in previous literatures and current study.
| Series | Country | Year | Case number | Methodology | RB1 | BRAF | TP53 | KRAS | APC | PIK3CA | PTEN | FBXW7 | MSI-H |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lee and Sung | South Korea | 2020 | 30 NECs | 382 gene | 14 (47%) | 7 (23%) | 13 (43%) | 16 (53%) | 11 (37%) | 3 (10%) | 1 (3%) | 3 (10%) | 1 (3%) |
| Shamir et al. | United State | 2019 | 24 NECs | 479 gene | 14 (58%) | 1 (4%) | 12 (50%) | 7 (29%) | 12 (50%) | 3 (13%) | 5 (21%) | 0 | 2 (8%) |
| Jesinghaus et al. | Germany | 2017 | 19 MANECs and 8 NECs | 32 gene | 1 (4%) | 9 (33%) | 13 (48%) | 6 (22%) | 8 (30%) | 1 (4%) | 3 (11%) | 3 (11%) | 2 (7%) |
| Woischke et al. | Germany | 2017 | 10 MANECs and 5 NECs | 50 gene | 5% | 3% | 13% | 11% | 10% | 5% | 1% | 3% | |
| Olevian et al. | United State | 2015 | 29 NECs | Sanger | 17 (59%) | 5 (17%) | 2 (7%) | ||||||
| Takizawa et al. | Japan | 2015 | 24 NECs | Sanger | 1 (4%) | 5 (21%) | 2 (8%) | 1 (4%) |
Sanger Sanger sequencing.